Treatment of chronic Hepatitis C with daclatasvir, sofosbuvir and simeprevir in patients from the reference hospital of infectology in central Brazil/  Tratamento da Hepatite C crônica com daclatasvir, sofosbuvir e simeprevir em pacientes do hospital de referência de infectologia do centro do Brasil

The drug treatment of hepatitis C represents a great therapeutic advance in favor of the elimination of the virus. The present study assessed the efficacy of treatment regimens involving direct action antivirals (DAAs), given to patients with chronic hepatitis C, attended at a referral hospital of infectology, central Brazil. This is a descriptive and cross - sectional study, based on the electronic database of the outpatient pharmacy, that evaluated the characteristics of patients and drug regimens involving DAA, from November 2015 to June 2017. Among 717 patients enrolled in this study, most of them had advanced liver fibrosis, were treatment naïve and HCV genotype 1 infected almost 80% of participants. A high efficacy of HCV treatment was achieved with 97% (95% CI: 94.9-98.2%) of SVR among the 431 patients who presented the results of viral load tests (HCV-RNA) at 12 weeks post-treatment. Patients infected with genotype 3 and who were cirrhotic had a lower SVR rate (87%). Treatment efficacy was not associated with age or sex among participants. The results of this study corroborate the findings in literature that showed a high efficacy of DAAs in the treatment of chronic hepatitis C, implemented through the clinical protocol and therapeutic guidelines for hepatitis C of the Ministry of Health in 2015. Many challenges must be overcome in order to combating viral hepatitis. In this context, the efficacy of HCV treatment it is an important issue to achieve the HCV elimination as a public health threat

Download Full-text

Distribution of hepatitis C virus genotypes and subtypes in a group of patients with chronic hepatitis C from Canton Sarajevo, 2012-2018

Acta Medica Saliniana ◽

10.5457/ams.v49i0.524 ◽

2019 ◽

Vol 49 ◽

Author(s):

Irma Salimović- Bešić ◽

Adna Kahriman ◽

Suzana Arapčić ◽

Amela Dedeić- Ljubović

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Hcv Rna ◽

Genotype 3 ◽

Hcv Genotype ◽

Hcv Genotypes ◽

Number Of Patients ◽

Subtype 1B

Background: Hepatitis C virus (HCV) genotypes and subtypes exhibit significant geographic variations.Aim: To analyse the distribution of genotypes/subtypes of HCV in a group of patients with chronic hepatitis C from Canton Sarajevo during 2012-2018.Material and methods:The study enrolled 247 human plasma samples of HCV-RNA positive patients with available results of HCV genotyping test.Results: During 2012-2018, the domination of subtypes 1a (34.01%), 1b (28.34%) and genotype 3 (23.89%) was registered. In 2012 and 2013, HCV subtype 1a was the most common (27/63; 42.86% and 17/40; 42.50%, respectively). In 2014, the leading HCV genotype/subtype were 3 and 1b (17/57; 29.82%). In 2015, the dominance of HCV genotype 3 (14/39; 35.90%) continued, while in 2016, the same number of HCV subtypes 1a and 1b (11/30; 36.67%) was recorded. Although in a small number of tested, during 2017, HCV subtype 1b was the most prevalent (7/14; 50.00%), and in 2018, it was replaced by a HCV subtype 1a (3/4; 75.00%). Distribution of HCV genotypes/subtypes by age group of patients varied significantly (p=0.000). The largest number of patients (71/247; 28.74%) belonged to the age category 30-39 years and HCV genotypes/subtypes 1, 3, 4, 1a and 1b were identified. Except in 2017, male gender significantly dominated (p=0.000). In males, HCV subtype 1a (68/170; 40.00%) was the most common, while in women it was HCV subtype 1b (44/77; 57.14%).Conclusion: This six-year retrospective study showed the time variations of the circulating HCV genotypes/subtypes among patients with chronic hepatitis C in Canton Sarajevo. Genotyping of the HCV has an important implications for diagnosis and treatment of the patients.

Download Full-text

FIB-4 INDEX:

The Professional Medical Journal ◽

10.29309/tpmj/2017.24.10.703 ◽

2017 ◽

Vol 24 (10) ◽

pp. 1501-1509

Author(s):

Fida Hussain Shaikh ◽

Shaista Zeb ◽

Kashif Aziz Siddiqui ◽

Muhammad Aamir Ghori ◽

Muhammad Sadik Memon ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Predictive Value ◽

Sampling Period ◽

University Hospital ◽

Diagnostic Validity ◽

Genotype 3 ◽

Cross Sectional ◽

Invasive Test

Objectives: To assess the diagnostic validity of FIB-4 for predicting hepaticfibrosis in patients of chronic hepatitis C genotype 3. Study Design: Cross-sectional study.Setting: Department of Gastroenterology and Hepatology, Isra University Hospital, Hyderabadthrough convenient sampling. Period: June 2013 to June 2014. Methods: Diagnostic validity ofFIB-4 index for predicting hepatic fibrosis was determined by measuring sensitivity, specificity,positive productive, negative predictive value, and compared these parameters with liverbiopsy. The liver histology was determined by METAVIR score. Results: A total 115 patientswere enrolled with mean and SD of age was 39.6 ± 9.3 years. Dividing FIB-4 index into threecategories as <1.45, 1.45 - 3.25, and >3.25; by using the Obuchowski method the AUROC was0.93 (with 95% CI 0.91, 0.95). When dividing the FIB-4 index in to three categories as <1.45,1.45 - <2.25 and >2.25; the AUROC by using Obuchowski method was 0.87 (with 95% CI 0.83,0.91). Similarly for the diagnosis of Cirrhosis (F = 4 METAVIR) on the predictive value of thenon-invasive test FIB-4 while using Obuchowski method the AUROC was 0.85 (with 95% CI0.83, 0.87). Conclusion: The FIB-4 index is a simple, inexpensive, non-invasive, and a quicktest for predicting liver fibrosis in patients of chronic Hepatitis C genotype 3.

Download Full-text

EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY

10.36106/5009819 ◽

2021 ◽

pp. 27-30

Author(s):

Manisha Thakur ◽

Anurag Chauhan ◽

Prashant Jambunathan ◽

Shikha Awasthi ◽

Thilagavathi K ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Sustained Viral Response ◽

Hcv Rna ◽

Hepatitis C Infection ◽

Genotype 3 ◽

Treatment Naïve

AIMS AND OBJECTIVES: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. We studied 67 treatment naive METHODS: patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram. Our results show that 70.5% (p<0.05) achieved a rapid vi RESULTS: rological response, 88.5% (p<0.05) achieved an end of treatment response and, similarly, an impressive 88.05% (p<0.05) showed a sustained virological response at the end of 12 weeks. One patient who developed a psoriasiform rash discontinued the medication and was excluded from the analysis, as duration of treatment had not been completed. No major dose related adverse events were reported. Sofosbuvir and Daclatasvir is an acceptable, well tolerated regimen for treatment naive, CONCLUSIONS: compensated patients with genotype 3 infection. Based on our observations and data, we recommend this as the rst line DAA for patient with compensated genotype 3 infection until medications with higher SVR 12 are available in the Indian market.

Download Full-text

CORRELATION BETWEEN HCV RNA VIRAL LOAD AND HOMA-IR IN CHRONIC HEPATITIS C PATIENTS

Current Internal Medicine Research and Practice Surabaya Journal ◽

10.20473/cimrj.v2i2.26537 ◽

2021 ◽

Vol 2 (2) ◽

pp. 29

Author(s):

Nadhya Allia ◽

Poernomo Boedi Setiawan ◽

Soebagijo Adi Soelistijo

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Load Level ◽

Hcv Rna ◽

Cross Sectional ◽

Viral Load Level ◽

Core Proteins ◽

Chronic Hepatitis C Patients

Background: Insulin resistance (IR) is one of the extrahepatic complications of hepatitis C virus (HCV) infection that needs to be recognized early. HOMA-IR is an effective way to measure insulin resistancy. Core proteins, NS-3, and NS-5 are the main components of HCV RNA proteins which are involved in the incidence of IR. Seeing this, a hypothesis was developed that the level of HCV RNA viral load was related to the HOMA-IR. This study was designed to identify the correlation between HCV RNA viral load with HOMA-IR in chronic hepatitis C patients.Method: We conducted a cross-sectional approach from the medical record of chronic hepatitis C patients at the outpatient clinic dr. Soetomo Hospital, Surabaya. A total of 30 patients aged >19 years old with complete medical records were included. Clinical and laboratory (including HCV RNA viral load level and HOMA-IR) data were obtained from the availability of medical records.Result: A total of 30 chronic hepatitis C patients, 17 (56.7%) were women and 13 (43.3%) were men, with mean age was 50.90 ± 7.17 years. The median of HCV RNA viral load level was 3,14 x106 IU/ml and the median of HOMA-IR was 4.50. The result of the Spearman correlation test showed a moderate positive association between HCV RNA viral load and HOMA-IR (r=0.537 ; p=0.002).Conclusion: A positive moderate correlation was obtained between HCV RNA viral load with HOMA-IR in chronic hepatitis C patients.

Download Full-text